Pricing
  1. US-listed companies
  2. Emergent BioSolutions Inc.
  3. Financials
  4. Research & development

Emergent BioSolutions Inc. (EBS)

Market cap
$446.71M
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202471-36.54%
Dec 31, 2023111-42.28%
Dec 31, 2022193-17.52%
Dec 31, 2021234-0.21%
Dec 31, 2020235+3.67%
Dec 31, 2019226+58.40%
Dec 31, 2018143+46.64%
Dec 31, 201797-10.07%
Dec 31, 2016108-29.68%
Dec 31, 2015154+28.40%
Dec 31, 2013120-0.24%
Dec 31, 2012120-3.69%
Dec 31, 2011125

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat